Patient 21 is a technology company.
Patient21 is dedicated to transforming healthcare by providing personalized treatment tailored to individual health issues, ensuring a strong doctor-patient relationship.
Patient 21 has raised $76.0M across 1 funding round.
Patient 21 has raised $76.0M in total across 1 funding round.
Patient 21 has raised $76.0M in total across 1 funding round.
Patient 21's investors include Matias Ventures, Pitango Venture Capital, Presight Capital, Republic Records.
Patient21 is a Berlin-based healthtech startup founded in 2019 that builds a "digi-physical" healthcare platform combining proprietary software with brick-and-mortar clinics, primarily focused on dental and outpatient care.[1][2][4] It serves patients and healthcare professionals across Germany by enabling seamless online booking, digital patient records, check-ins, billing, insurance handling, diagnosis support, and treatment planning, solving fragmented healthcare data access that delays care and raises costs.[1][2][3] The platform empowers doctors to focus on patients by automating admin tasks and gives patients proactive access to their data; it currently handles over 300,000 annual visits across 25-50+ clinics in 19 cities, with 300%+ growth since 2020 and plans for European expansion.[1][2][3][6]
Patient21 was co-founded in 2019 by serial entrepreneur Christopher Muhr (CEO, ex-COO of Auto1 and Groupon, with successful exits) and Nicolas Hantzsch, inspired by Muhr's personal cancer treatment experience where siloed data hindered doctors' access to critical patient information.[1][2][3] Muhr, one of Europe's respected tech founders (Auto1 listed on Frankfurt exchange in 2021), shifted focus to healthcare to create complete, accessible patient records via a digitally enabled system.[1] Early traction came rapidly: emerging from stealth in 2023 with $142M funding (including a record €100M/$108M Series C led by Pitango), fueling 300% growth and clinic network buildup.[1][2][3]
Patient21 rides the digital health transformation trend, digitizing Europe's analog, fragmented healthcare amid staff shortages, aging populations, chronic disease surges, and post-pandemic telemedicine acceleration—timing aligns with supply constraints making efficient platforms essential.[2][3] Market forces like rising costs and data silos favor its model, which boosts efficiency without replacing human care, positioning it as a leader in "digi-physical" healthtech over pure virtual players.[1][2] It influences the ecosystem by setting standards for doctor-designed software, expanding clinic networks (Germany to Europe by 2025, global by 2030), and pioneering AI diagnostics, potentially reshaping outpatient/dental care delivery.[1][3]
Patient21's momentum—record 2023 funding, explosive growth, and software maturity—positions it for dominance in Europe's healthtech, with near-term Europe-wide clinic rollout and telehealth/AI enhancements driving more visits and markets.[1][2][3] Trends like AI diagnostics, chronic care demands, and regulatory pushes for interoperable data will propel it, evolving from dental/outpatient focus to comprehensive human medicine while maintaining its doctor-patient core.[2][3] As it scales globally by decade's end, Patient21 could redefine accessible, data-driven care, turning Muhr's personal insight into a healthcare revolution.[1]
Patient 21 has raised $76.0M across 1 funding round. Most recently, it raised $76.0M Series C in May 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2023 | $76.0M Series C | Matias Ventures, Pitango Venture Capital, Presight Capital, Republic Records |